All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Skin & Hair comparison

Matrixyl (Palmitoyl Pentapeptide-4) vs Melanotan II

An educational, source-based comparison of Matrixyl (Palmitoyl Pentapeptide-4) and Melanotan II — how each peptide works, what it's researched for, and what to know before going deeper.

Skin · Collagen
Matrixyl (Palmitoyl Pentapeptide-4)

Topical matrikine researched for collagen stimulation.

Mechanism

A signal peptide that mimics the procollagen-I fragment, stimulating fibroblasts to produce collagen, elastin, and glycosaminoglycans in topical cosmetic research.

Research areas
  • Dermal collagen synthesis
  • Fine lines and skin firmness
Considerations
  • Well tolerated in topical use.
  • Modest improvements; not equivalent to retinoids.
Full Matrixyl (Palmitoyl Pentapeptide-4) profile →
Pigmentation · Melanocortin
Melanotan II

Melanocortin agonist researched for tanning response and libido.

Mechanism

A non-selective melanocortin receptor agonist that stimulates eumelanin production via MC1R and influences appetite, libido, and erectile function via MC3R/MC4R.

Research areas
  • UV-independent pigmentation
  • Erythropoietic protoporphyria (related compound, afamelanotide)
  • Sexual function (overlap with PT-141)
Considerations
  • Not FDA-approved.
  • Risk of new or changing nevi — dermatologic monitoring is essential.
  • Common side effects: nausea, flushing, spontaneous erections, appetite suppression.
Full Melanotan II profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

Matrixyl (Palmitoyl Pentapeptide-4)
Preliminary

Early-stage research; conclusions are tentative.

1 cited study
Melanotan II
Preliminary

Early-stage research; conclusions are tentative.

1 cited study

Study-by-study comparison

PeptideStudySourceYearSummary
Matrixyl (Palmitoyl Pentapeptide-4)Palmitoyl pentapeptide-4 in anti-aging skincareInternational Journal of Cosmetic Science2005Improved wrinkle parameters versus placebo in topical trial.
Melanotan IIMelanotan and melanocortin receptor pharmacologyPeptides2005Reviewed pigmentation and behavioral effects of MT-II in animal and human studies.

Side-effect & safety grid

Matrixyl (Palmitoyl Pentapeptide-4)
  • Well tolerated in topical use.
  • Modest improvements; not equivalent to retinoids.
Melanotan II
  • Not FDA-approved.
  • Risk of new or changing nevi — dermatologic monitoring is essential.
  • Common side effects: nausea, flushing, spontaneous erections, appetite suppression.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

Matrixyl (Palmitoyl Pentapeptide-4) vs Melanotan II — Key differences

  • Class: Matrixyl (Palmitoyl Pentapeptide-4) is classified as Skin · Collagen, while Melanotan II is Pigmentation · Melanocortin.
  • Primary research focus: Matrixyl (Palmitoyl Pentapeptide-4)dermal collagen synthesis; Melanotan IIuv-independent pigmentation.
  • Tag: Skin vs Skin · Pigmentation.

Related comparisons